Financing ·
Cardiff Oncology reported second quarter 2026 financial results and provided a business update
CRDFCardiff Oncology, Inc.
Cardiff Oncology reported second quarter 2026 financial results and provided a business update. The company completed a $10 million registered direct offering of common stock and warrants to support working capital. As of June 30, 2026, Cardiff held approximately $34.5 million in cash, cash equivalents, and short-term investments. Net cash used in operating activities for the six months ended June 30, 2026 was approximately $24.1 million. The company plans to initiate a Phase 3 registrational trial of onvansertib in first-line RAS-mutated metastatic colorectal cancer in Q1 2027, subject to securing additional financing. Cardiff Oncology is a clinical-stage biotechnology company developing novel cancer therapies leveraging PLK1 inhibition.